Monopar和NorthStar宣布选定uPRIT候选药物作为重症新冠肺炎潜在治疗药物
10 déc. 2020 08h30 HE
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特和威斯康星州贝洛伊特, Dec. 10, 2020 (GLOBE NEWSWIRE) -- 合作开发尿激酶型纤溶酶原激活物受体放射免疫疗法（uPRIT）用于重症新冠肺炎患者潜在治疗的Monopar Therapeutics Inc.（Nasdaq: MNPR）和NorthStar Medical Radioisotopes,...
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
10 déc. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase...
Monopar宣布启动2b/3期（VOICE）试验以评估Validive®预防化疗引起口咽癌（OPC）患者重度口腔粘膜炎（SOM）的效果。
08 déc. 2020 08h46 HE
|
Monopar Therapeutics Inc.
伊利诺斯州威尔梅特, Dec. 08, 2020 (GLOBE NEWSWIRE) -- 主要专注于开发专有技术疗法以延长癌症患者寿命或提高其生活质量的临床分期生物制药公司Monopar Therapeutics Inc.（Nasdaq: MNPR）今天宣布，该公司运用Validive®防止口咽癌患者放化疗引发重度口腔粘膜炎的试验（以下称“VOICE”试验）2b/3期已启动并开始招募患者。 ...
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
08 déc. 2020 08h30 HE
|
Monopar Therapeutics Inc.
There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM WILMETTE, Ill., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a...
Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
12 nov. 2020 09h15 HE
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 Clinical Trial on Track to Start Before Year-endIssuance of New Patents For ValidiveCamsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021 WILMETTE, Ill., Nov. 12,...
Monopar宣布其新获专利将扩大对2b/3期临床领先候选药物Validive®的保护
09 nov. 2020 19h33 HE
|
Monopar Therapeutics Inc.
伊利诺伊州维尔梅特, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（Nasdaq:...
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®
09 nov. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020
14 sept. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at...
Monopar和NorthStar就重症新冠肺炎新型潜在疗法的测试与得克萨斯肺损伤研究所达成协作
09 sept. 2020 10h02 HE
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特、威斯康星州贝洛伊特和得克萨斯州泰勒, Sept. 09, 2020 (GLOBE NEWSWIRE) -- 合作开发尿激酶型纤溶酶原激活物受体放射免疫疗法（uPRIT）用于重症新冠肺炎患者潜在治疗的Monopar Therapeutics Inc.（Nasdaq: MNPR）和NorthStar Medical Radioisotopes,...
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
09 sept. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing...